Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
life sciences
national blog main
startups
vc
4
×
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
deals
financing
ipo
accent therapeutics
acetylon pharmaceuticals
aducanumab
alnylam
alzheimer's disease
amblyotech
ambys medicines
arena pharmaceuticals
artie suckow
asklepios biopharmaceutical
azacitidine
beta-thalassemia
bioeurope
biogen
biomarin pharmaceutical
boston
boulder/denver blog main
boulder/denver top stories
brainvectis
c. greg guyer
cancer
cara therapeutics
cell therapy
What
medicines
4
×
new
biotech
developing
diseases
drugs
startup
activity
advance
aiming
aims
ambys
approach
approvals
based
big
bio
biogen
biologics
called
clamped
considered
control
covid
deadly
deal
debuted
debuts
delays
deliver
dtx
economic
epigenetic
epigenetics
fast
fda
field
flagship’s
formed
future
Language
unset
Current search:
medicines
×
vc
×
biotech
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
